Effectiveness of BEHI and CBH on emotional and pain-related outcomes in chronic low back pain

Comparison of the Effects of Bioenergy Economy Health Improvement Therapy (BEHI) and Cognitive Behavioral Hypnotherapy (CBH) on Pain Catastrophizing, Pain Anxiety, Emotion Regulation, and Emotional Self-Efficacy in Individuals with Chronic Low Back Pain of Muscular Origin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250629066288N1

Enrollment

Registered

2025-07-05

Start date

2025-07-23

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic nonspecific low back pain. Chronic low back pain, not elsewhere classified

Interventions

Intervention group: In this study, the intervention includes Cognitive Behavioral Hypnotherapy and Bio-Energy Health Improvement. Cognitive Behavioral Hypnotherapy is a combination of cognitive-behavi

Eligibility

Sex/Gender

All

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Age between 20 and 45 years_ At least one month and at most six months since the last diagnosis_Education diploma or higher_No acute or chronic psychological disorders

Exclusion criteria

Exclusion criteria: Unwillingness to participate or withdrawal from treatment continuation_Receiving parallel psychological or psychiatric treatments_Disease relapse requiring hospitalization_Absence from more than three sessions

Design outcomes

Primary

Measure	Time frame
First Outcome Variable:Pain Catastrophizing Score based on the Pain Catastrophizing Scale (PCS)In this study, pain catastrophizing is assessed using the standardized PCS questionnaire. This scale consists of 13 items, with higher scores indicating greater levels of pain catastrophizing.Second Outcome Variable:Pain Anxiety Score based on the Pain Anxiety Subscale of the Pain Anxiety Symptoms Scale (PASS)Pain anxiety is measured using the pain anxiety subscale of the PASS questionnaire. This tool evaluates the degree of worry, fear, and avoidance related to the experience of pain.Third Outcome Variable:Emotion Regulation Behavior Score based on the Emotion Regulation Questionnaire (ERQ) Behavior Regulation SubscaleEmotion regulation behavior is assessed using the relevant subscale of the ERQ questionnaire, which examines an individual’s behavioral responses to emotional experiences.Fourth Outcome Variable:Emotional Self-Efficacy Score based on the Emotional Self-Efficacy Scale (ESES)Participants’ level of emotional self-efficacy is measured using the ESES questionnaire, which assesses the individual’s ability to manage their emotions across different situations. Timepoint: Time Points of Measurement for the Primary Outcome:The primary outcomes of the study will be measured at four time points:At the beginning of the study, before the intervention (baseline)_At 4 weeks after the start of the intervention_At 8 weeks after the start of the intervention_And at the end of follow-up at week 12.At each time point, the questionnaires related to Pain Catastrophizing (PCS), Pain Anxiety (PASS), Emotion Regulation Behavior (ERQ), and Emotional Self-Efficacy (ESES) will be completed. Method of measurement: Pain catastrophizing is measured using the Pain Catastrophizing Scale, which consists of thirteen items.Pain anxiety is measured using the pain anxiety subscale of the Pain Anxiety Symptoms Scale.Emotion regulation behavior is assessed using the behavior regulation subscale of	—

Measure

Time frame

First Outcome Variable:Pain Catastrophizing Score based on the Pain Catastrophizing Scale (PCS)In this study, pain catastrophizing is assessed using the standardized PCS questionnaire. This scale consists of 13 items, with higher scores indicating greater levels of pain catastrophizing.Second Outcome Variable:Pain Anxiety Score based on the Pain Anxiety Subscale of the Pain Anxiety Symptoms Scale (PASS)Pain anxiety is measured using the pain anxiety subscale of the PASS questionnaire. This tool evaluates the degree of worry, fear, and avoidance related to the experience of pain.Third Outcome Variable:Emotion Regulation Behavior Score based on the Emotion Regulation Questionnaire (ERQ) Behavior Regulation SubscaleEmotion regulation behavior is assessed using the relevant subscale of the ERQ questionnaire, which examines an individual’s behavioral responses to emotional experiences.Fourth Outcome Variable:Emotional Self-Efficacy Score based on the Emotional Self-Efficacy Scale (ESES)Participants’ level of emotional self-efficacy is measured using the ESES questionnaire, which assesses the individual’s ability to manage their emotions across different situations. Timepoint: Time Points of Measurement for the Primary Outcome:The primary outcomes of the study will be measured at four time points:At the beginning of the study, before the intervention (baseline)_At 4 weeks after the start of the intervention_At 8 weeks after the start of the intervention_And at the end of follow-up at week 12.At each time point, the questionnaires related to Pain Catastrophizing (PCS), Pain Anxiety (PASS), Emotion Regulation Behavior (ERQ), and Emotional Self-Efficacy (ESES) will be completed. Method of measurement: Pain catastrophizing is measured using the Pain Catastrophizing Scale, which consists of thirteen items.Pain anxiety is measured using the pain anxiety subscale of the Pain Anxiety Symptoms Scale.Emotion regulation behavior is assessed using the behavior regulation subscale of

—

Secondary

Measure	Time frame
The secondary outcome variable includes improvement in quality of life, assessed using the standard Short Form Health Survey 36 (SF-36) questionnaire. This questionnaire evaluates various aspects of physical and mental health, with higher scores indicating better quality of life. Additionally, participants’ levels of depression and anxiety will be measured as secondary outcomes using the Beck Depression and Anxiety Inventories or the Hospital Anxiety and Depression Scale (HADS). Timepoint: The time points for measuring the secondary outcome variable are as follows:At the beginning of the study, before the intervention (baseline)Four weeks after the start of the interventionEight weeks after the start of the interventionAnd at the end of follow-up at week 12. Method of measurement: The secondary outcome variable is measured using the Short Form Health Survey 36 (SF-36) questionnaire to assess quality of life, as well as the Beck Depression and Anxiety Inventories or the Hospital Anxiety and Depression Scale (HADS) to evaluate participants’ levels of depression and anxiety. All questionnaires are self-administered.	—

Measure

Time frame

The secondary outcome variable includes improvement in quality of life, assessed using the standard Short Form Health Survey 36 (SF-36) questionnaire. This questionnaire evaluates various aspects of physical and mental health, with higher scores indicating better quality of life. Additionally, participants’ levels of depression and anxiety will be measured as secondary outcomes using the Beck Depression and Anxiety Inventories or the Hospital Anxiety and Depression Scale (HADS). Timepoint: The time points for measuring the secondary outcome variable are as follows:At the beginning of the study, before the intervention (baseline)Four weeks after the start of the interventionEight weeks after the start of the interventionAnd at the end of follow-up at week 12. Method of measurement: The secondary outcome variable is measured using the Short Form Health Survey 36 (SF-36) questionnaire to assess quality of life, as well as the Beck Depression and Anxiety Inventories or the Hospital Anxiety and Depression Scale (HADS) to evaluate participants’ levels of depression and anxiety. All questionnaires are self-administered.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzad Goli

Health Knowledge Institute

daneshtandorosti@gmail.com031536671917

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026